EMA recommends conditional approval of second COVID-19 vaccine

6 January 2021

Lagging behind the US regulator, the European Medicines Agency today announced its recommendation for conditional marketing authorization to be granted to another novel coronavirus vaccine, this time for US biotech firm Moderna’s (Nasdaq: MRNA) product, now called COVID-19 Vaccine Moderna and previously dubbed mRNA-1273, in people aged 18 years and more.

Moderna, whose shares rose 3.3% to $112.80 in early trading, has negotiated a deal with the European Commission to supply 80 million doses of its vaccine for member states, with the option for an additional 80 million doses, at a price of 20 euros (~$24.60) per doses agreed with the EC. The company expects to be able to produce 1 billion doses this year.

The first deliveries of COVID-19 Vaccine Moderna to European countries from Moderna’s dedicated non-US supply chain are expected to begin next week, the company stated, also noting that the EMA had exercised its option for a total of 160 million doses.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK